Evaluation of the Efficacy of Two Probiotic Strains for Irritable Bowel Syndrome

Phase 2

Completed

• Conditions: Irritable Bowel Syndrome
• Interventions: Dietary Supplement: Lactobacillus paracasei HA-196; Dietary Supplement: Bifidobacterium longum R0175; Other: Placebo

• Registration Number: NCT02213172
• Lead Sponsor: KGK Science Inc.

Brief Summary

The purpose of this study is to determine if two different probiotic strains, Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175, are effective in helping subjects manage the symptoms of IBS

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2014-08-07
• Study First Submitted QC: 2014-08-07
• Study First Posted: 2014-08-11
• Study Start: 2014-10-30
• Primary Completion: 2018-02-15
• Study Completion: 2018-03
• Status Verified: 2020-03
• Last Update Submitted: 2020-03-11
• Last Update Posted: 2020-03-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 285

Inclusion Criteria

• Male and female aged 18 years and older.

• IBS diagnosis according to Rome III criteria and referral to this study by a clinician. That is, recurrent abdominal pain or discomfort (i.e., uncomfortable sensation other than pain) at least 2 days/month in the last 3 months (response to question 1 of the IBS Rome III module questionnaire > 2) associated with 2 or more of the following:

  • Improvement with defecation (response to question 4 of the IBS Rome III module questionnaire > 0);
  • Onset associated with a change in stool frequency (response to question 5 or 6 of the IBS Rome III module questionnaire > 0);
  • Onset associated with a change in stool form (appearance). (response to question 7 or 8 of the IBS Rome III module questionnaire > 0).

• For women, the abdominal pain or discomfort should be experienced during days other than menstrual bleeding (response to question 2 of the IBS Rome III module questionnaire = 0 or 2)

• Criterion must be fulfilled for the last 3 months with symptom onset at least 6 months prior to screening (response to question 3 of the IBS Rome III module questionnaire = 1).

• A copy of the IBS module is provided in Appendix A: IBS Rome III Module Questionnaire

• Participants from the general population who have IBS symptoms, without a previous diagnosis, will be assessed by the Principle Investigator and included in the study if differential diagnosis confirms IBS. The Principle Investigator will confirm the diagnosis of IBS in any potential participants who have a previous diagnosis of IBS.

• Subjects experiencing a pain/discomfort frequency of at least 2 days a week during the run-in period. At visit 2, subjects will be asked "In the last 2 weeks, how often each week did you have discomfort or pain anywhere in your abdomen? ". The answer must be at least 2.

• Subjects diagnosed with IBS who have depression may be included

• Absence of black color (melena) or blood in stools.

• Willingness to complete questionnaires, records, and diaries associated with the study and to complete all clinic visits.

• Willingness to discontinue consumption of probiotics (e.g. yogurts, with live, active cultures or supplements).

• Able to provide informed consent.

Exclusion Criteria

• Subjects with a history of suicidal ideation, or current suicidal ideation

• Previous history of gastrointestinal surgery (except appendectomy, cholecystectomy, hernia repair, or hemorrhoidectomy).

• Other gastrointestinal diseases (except hemorrhoids and uncomplicated diverticula), as assessed by ultrasonography, colonoscopy, or rectoscopy, or history of Clostridium difficile-associated diarrhea.

• A family history (immediate family i.e. siblings and parents) of colorectal cancer, inflammatory bowel disease and/or celiac spruce.

• Co-existing organic gastrointestinal disease.

• Presence of rectal bleeding, recent weight loss (greater than 5 kg in the past month) or iron deficiency anemia.

• History of, or current diagnosis of, liver disease, kidney disease, pulmonary disease, cardiovascular disease, pancreatic disease, any cancer.

• Presence of immune-compromised conditions such as AIDS, lymphoma or undergoing long-term corticosteroid treatment

• Presence or history of neurological disorders, or significant psychiatric illness.

• History of, or current diagnosis of, pelvic floor dyssynergia.

• Positive drug or alcohol screen or recent history of drug or alcohol abuse (within 3 years of screening).

• Milk or soy allergy.

• Use of another investigational product within 3 months of the screening visit. The screened participant could be eligible to participate after a washout period.

• Positive pregnancy test in women of child-bearing potential.

• Pregnant or breast-feeding or planning on becoming pregnant.

• Women of child-bearing potential not using effective contraception. Acceptable methods of birth control include:

  • Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
  • Intrauterine devices
  • Vasectomy of partner (shown successful as per appropriate follow-up)
  • Double barrier method (use of physical barrier by both partners)

• Use of any antibiotic drug (e.g., neomycin, rifaximin) within 1 month of screening. The screened participant could be eligible to participate after a 1 month washout period.

• Use of PPI or H2R antagonist within 1 month of screening. The screened participant could be eligible to participate after a 1 month washout period.

• Daily use of non-steroidal anti-inflammatory drugs, cortisone, or other anti-inflammatory drugs 1 month prior to screening. The screened participant could be eligible to participate after a 1 month washout period.

• Current use, or use within the past 1 month, of narcotics or other medications for IBS symptom management (e.g. alosetron, tegaserod, lubiprostone, antispasmodics, antidiarrheals, laxatives, antipsychotics, tricyclic anti-depressants, selective serotonin reuptake inhibitors (SSRIs)). Subjects taking a stable dose of anti-depressants for at least 30 days with no plan to change dosage during the trial will be eligible for inclusion in the study.

• Regular use of anti-diarrhea medications and laxatives. Occasional use is permitted prior to screening (≤ than once a month); if current use is >once per month a one month wash out period is needed prior to screening.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Lactobacillus paracasei HA-196	Lactobacillus paracasei HA-196	10 x 10\^9 CFU per capsule, 1 capsule daily for 8 weeks
Bifidobacterium longum R0175	Bifidobacterium longum R0175	10 x 10\^9 CFU per capsule, 1 capsule daily for 8 weeks
Placebo	Placebo	1 capsule daily for 8 weeks

Primary Outcome Measures

Name	Time	Method
IBS Symptom Severity Score	8 Weeks	Assessed using IBS Severity Scoring System Questionnaire, Part I.

Secondary Outcome Measures

Name	Time	Method
Bowel Habit Satisfaction	8 weeks	Assessed by question 3 of the IBS-SSS
Abdominal Pain Intensity	8 weeks	Mean weekly score. Assessed using IBS-SSS
Anxiety and Depression	8 weeks	Assessed by administering the HADS questionnaire
Abdominal pain frequency	8 weeks	Assessed using IBS Severity Scoring System Questionnaire, Part I(c)
Abdominal distension/tightness	8 weeks	Assessed using the IBS-SSS Question 2(b)
Severity of IBS Symptoms	4 weeks	Assessed by administration of the IBS-SSS questionnaire, difference from baseline to week 4
Impact of IBS symptoms on Quality of Life	8 weeks	Assessed by administration of the IBS-QOL Questionnaire
IBS Symptom Severity Score by IBS Subtype	8 weeks	Assessed using IBS Severity Scoring System Questionnaire, Part I.
Number of Responders	8 weeks	A responder is defined as a participant who has at least a 20% improvement in the IBS-SSS severity score after 8 weeks of supplementation
Severity of straining	8 weeks	Assessed using IBS daily diary, 5 point ordinal scale
Stool Frequency	8 weeks	Assessed using the IBS Daily Diary
Health Status	8 weeks	Assessed by administration of the SF-36 questionnaire
Stool Consistency	8 weeks	Assessed using the Bristol Stool Scale included in the IBS Daily Diary

Trial Locations

Locations (1)

KGK Synergize Inc.; 🇨🇦 London, Ontario, Canada